GLPG 1690

Drug Profile

GLPG 1690

Alternative Names: GLPG-1690

Latest Information Update: 28 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Galapagos NV
  • Class Anti-inflammatories; Antifibrotics; Azetidines; Imidazoles; Nitriles; Piperazines; Small molecules; Thiazoles
  • Mechanism of Action ENPP2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic pulmonary fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Idiopathic pulmonary fibrosis
  • Preclinical Chronic obstructive pulmonary disease

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for phase-I development in Idiopathic-pulmonary-fibrosis(In volunteers) in Belgium (PO, Suspension)
  • 01 Jun 2018 Galapagos completes a phase I drug-drug interaction trial in healthy male volunteers in the UK (NCT03515382)
  • 20 May 2018 Galapagos announces intention to submit NDA to the US FDA and MAA to EMA for idiopathic pulmonary fibrosis in USA and European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top